No Data
Expert Outlook: Nurix Therapeutics Through The Eyes Of 14 Analysts
Nurix Therapeutics Is Maintained at Outperform by RBC Capital
Nurix Therapeutics Analyst Ratings
RBC Capital Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Raises Target Price to $26
Express News | Nurix Therapeutics Inc : RBC Raises Target Price to $26 From $23
Insider Sale: CFO Houte Van Sells 20,000 Shares of Nurix Therapeutics Inc (NRIX)